Trodelvy Cuts Disease Progression Risk by 38% in TNBC Trial
October 20, 2025
Gilead Sciences, Inc. shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS)